DBVT
NASDAQDBV Technologies S.A.
Price$14.75-0.23 (-1.57%)
01:30 PM07:45 PM
News · 26 weeks50+11%
2026-01-182026-07-12
Mix3190d
- Other14(45%)
- SEC Filings13(42%)
- Earnings3(10%)
- Offering1(3%)
Latest news
25 items- PRDBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of SalesChâtillon, France, July 17, 2026 DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company, today announced that it has filed a new automatically effective shelf registration statement on Form S-3ASR (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC"), which includes a base prospectus and a sales agreement prospectus supplement refreshing the Company’s previously established at-the-market offering program (the "ATM Program") by filing a prospectus supplement for sales of up to $150 million of American Depositary Shares ("ADS"). The ATM Prog
- SECDBV Technologies S.A. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - DBV Technologies S.A. (0001613780) (Filer)
- PRDBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the ReportChâtillon, France, July 16, 2026 DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company (the "Company"), today announced the filing, for the semester ended June 30, 2026, of its Half-Year Report with the French market authority, "Autorité des Marchés Financiers" ("AMF"). The 2026 Half-Year Report can be consulted or downloaded from the Company’s website (www.dbv-technologies.com) in the section Investors/Financial Information, and on the AMF website (www.amf-france.org), in French only. About DBV Technologies DBV Technologies is a late-stage biopharmaceut
- SECSEC Form 10-Q filed by DBV Technologies S.A.10-Q - DBV Technologies S.A. (0001613780) (Filer)
- PRDBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business UpdateChâtillon, France, July 16, 2026 DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update Continued productive engagement with the FDA in support of the BLA for the VIASKIN® Peanut Patch in children aged 4 through 7 years, with submission of the BLA anticipated in the third quarter of 2026Reported cash and cash equivalents of $174.9 million as of June 30, 2026, funding into third quarter of 2027 DBV will host a conference call today, July 16, at 5:00pm ET DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today reported financial results for the Second Quarter and Half-Year of 2026. The quarterly and Half-Year financial statements
- PRDBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026Châtillon, France, July 14, 2026 DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 Company to host investor conference call and webcast at 5:00 p.m. ET DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Thursday, July 16th, at 5:00 p.m. ET to review its second quarter 2026 financial results and provide a business update. Interested participants may access this call via the teleconferencing numbers below and by asking to join the DBV Technologies Second Quarter 2026 Results call: United States: +1-877-344-8082 International: +1-2
- PRHalf-Year Report on the DBV Technologies Liquidity Contract with ODDO BHFAMF Regulated InformationChâtillon, France, July 6, 2026 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF relating to DBV Technologies shares (the "Liquidity Contract"). The Liquidity Contract is implemented in accordance with AMF Decision No. 2021-01 of June 22, 2021 on liquidity contracts on equity securities accepted as a market practice. When the Liquidity Contract with ODDO BHF was implemented, as of July 1, 2018, the following assets were included in the liquidity account: 41,159 DBV Technologies shares,€ 432,367
- SECSEC Form 8-K filed by DBV Technologies S.A.8-K - DBV Technologies S.A. (0001613780) (Filer)
- PRDBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for FilingChâtillon, France, June 29, 2026 DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing DBV has been engaged in extensive discussions with the FDA in preparation of its BLA for the VIASKIN® Peanut Patch in children aged four through seven yearsThe objective of the detailed, iterative engagement was to ensure a complete, efficient, and timely FDA review of the BLA, once submittedThe Agency has not requested additional dataDBV will take additional time to incorporate the FDA feedback and anticipates submitting the BLA in the third quarter of 2026D
- PRDBV Technologies Announces Inclusion in the Euronext Tech Leaders IndexChâtillon, France, June 23, 2026 DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced that the Company has been included in the Euronext Tech Leaders index. Inclusion in the index went into effect on June 22, 2026. The Euronext Tech Leaders index is part of Euronext's broader initiative to spotlight high-growth European companies across technology and adjacent sectors — including software, biotech, fintech, cleantech, and semiconductors — among institutional investors. With more than 100 companies listed across Euronext's European markets (Amsterdam, Brussels, Dublin, Lisbon, Mila
- PRDBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare ConferenceChâtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company, today announced that company management will participate in 1-on-1 investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, in Miami, FL. Mr. Daniel Tassé, CEO, will not be available for the previously scheduled fireside chat due to an unavoidable disruption of planned travel to the conference. About DBV TechnologiesDBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies an
- PRDBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026Châtillon, France, June 8, 2026 DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 In the Phase 3 VITESSE study, VIASKIN® Peanut Patch demonstrated statistically significant efficacy vs. placebo in the subgroups of children with peanut allergy who also had another common atopic condition, including asthma, concomitant food allergy, or atopic dermatitis.DBV will also present the clinical trial design of its recently initiated THRIVE study, which will assess the efficacy and safety of the VIASKIN® Peanut Patch in achieving ad lib consumption of peanuts in infants ages 6 through 12 months with peanut allergy
- PRDBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceChâtillon, France, June 5, 2026 DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 9:20 AM ET, in Miami, FL. A live webcast of the fireside chat can be accessed here, and will also be available on the Events section of the Company's Investors website: https://dbv-technologies.com/investor-overview/events/, with an archived replay accessible for 90 days following the event. Ab
- SECSEC Form 8-K filed by DBV Technologies S.A.8-K - DBV Technologies S.A. (0001613780) (Filer)
- SECSEC Form S-8 filed by DBV Technologies S.A.S-8 - DBV Technologies S.A. (0001613780) (Filer)
- PRInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of sharesTotal number of voting rights05/31/2026 296,061,497 Total gross of voting rights: 296,061,497 Total net* of voting rights: 295,906,088 * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version
- PRDBV Technologies Announces the Results of its 2026 Combined General MeetingChâtillon, France, June 3, 2026 DBV Technologies Announces the Results of its 2026 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (TRQX:DBVp), a late stage biopharmaceutical company (the "Company"), held its Combined General Meeting (the "General Meeting"). The General Meeting was chaired by Michel de Rosen, Chairman of the Board of Directors (the "Board"). The Company's shareholders approved all resolutions submitted by the Board. The resolutions and voting results are posted on the Company's website: 2026 Annual General Meeting | DBV Technologies About DBV TechnologiesDBV Technologies is a late-stage biopharmaceutical company developing tre
- SECSEC Form 8-K filed by DBV Technologies S.A.8-K - DBV Technologies S.A. (0001613780) (Filer)
- PRDBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut AllergyChâtillon, France, June 2, 2026 DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy The study is evaluating the efficacy and safety of the VIASKIN® Peanut Patch in achieving ad lib consumption of dietary peanut in infants ages 6 through 12 months with peanut allergyFirst participant screened by Dr. Douglas Mack, Assistant Clinical Professor in the Department of Pediatrics at McMaster University, Ontario DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today announced that the first participant has been screened in the THRIVE Phase 2 clinical study evaluating
- PRCombined General Meeting of June 3, 2026Châtillon, France, May 13, 2026 Combined General Meeting of June 3, 2026 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company (the "Company"), will hold its Combined General Meeting (the "General Meeting") on June 3, 2026, at 10:00 a.m. CEST (04:00 a.m. EST) at the Company's headquarters located at IRO Building, 107 Avenue de la République, 92320 Châtillon, France. The preliminary notice (avis de réunion) containing the detailed agenda, draft resolutions as well as instructions to participate and vote for this General Meeting was published in the French "Bulletin des Annonces L
- SECAmendment: SEC Form SCHEDULE 13G/A filed by DBV Technologies S.A.SCHEDULE 13G/A - DBV Technologies S.A. (0001613780) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by DBV Technologies S.A.SCHEDULE 13G/A - DBV Technologies S.A. (0001613780) (Subject)
- PRDBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NasdaqChâtillon, France, May 12, 2026 DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq, which is being held May 19, 2026 in New York, NY. Mr. Tassé's presentation is scheduled for Tuesday, May 19, at 9:00 am ET. A live webcast of the fireside chat can be accessed here and will also be available on the Events section of the Company's Investors website: https://dbv-technologies.com/investor-o
- SECSEC Form DEF 14A filed by DBV Technologies S.A.DEF 14A - DBV Technologies S.A. (0001613780) (Filer)
- SECSEC Form 8-K filed by DBV Technologies S.A.8-K - DBV Technologies S.A. (0001613780) (Filer)
DBVT FAQ
7 questionsWhat does DBV Technologies S.A. do?
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical...Where does DBVT stock trade?
DBV Technologies S.A. (DBVT) is listed on NASDAQ.What sector and industry is DBVT in?
DBV Technologies S.A. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did DBV Technologies S.A. go public?
DBV Technologies S.A. (DBVT) completed its IPO in 2014.What are analysts saying about DBVT?
DBV Technologies S.A. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight with a $4200.00 price target on 2025-12-15.What companies are similar to DBVT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare DBVT side-by-side with any of them on Quantisnow.How can I track DBVT on Quantisnow?
Quantisnow aggregates DBV Technologies S.A.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DBVT to receive live email and push alerts on every new disclosure.